SMMT insider buying & filings

← All candidates

SMMTSummit Therapeutics Inc.

NasdaqGM · Healthcare · $11.84B

$17.49

+0.73% · Sep 18

Nine insider buys in the last year — $114.62M in all.
Nothing in the last fortnight.

Last Form 4 Jun 12 · scanned 13m ago

Price · 1Y · daily● 9 buys◆ 12 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$11.84B

Float

130.7M

17% public

Short % float

Pro

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Co-Chief Executive Officer

Zanganeh Mahkam

Bought $49.99M on Jun 12 — 3,810,000 sh @ $13.12, held indirect, 0.7% of their stake.

0 of 1 position beat the S&P

median -12.6% vs S&P +5.0% same spans · 5 buy-days · 1 positions still open

Co-Chief Executive Officer

Duggan Robert W

Bought $49.99M on Jun 12 — 3,810,000 sh @ $13.12, held direct, 0.7% of their stake.

1 of 3 positions beat the S&P

median -1.3% vs S&P +5.0% same spans · 8 buy-days · 1 positions still open

Director

Xia Yu

Bought $10.00M on Oct 21 — 533,617 sh @ $18.74, held indirect, 1.7% of their stake.

1 of 1 position beat the S&P

median +12.7% vs S&P +4.3% same spans

Institutional stakes

▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing

25 filingsnewest first

13D/ADuggan Robert WSep 13

13D/AZanganeh MahkamMar 13

13D/ADuggan Robert WFeb 16

13G/APolar Capital Holdings PlcFeb 14

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Jun 12BUYZanganeh Mahkam10%Co-Chief Executive Officer+0.7%indirect3,810,000 @ $13.12$49.99M

Jun 12BUYDuggan Robert W10%Co-Chief Executive Officer+0.7%direct3,810,000 @ $13.12$49.99M

Jun 4BUYDuggan Robert W10%Co-Chief Executive Officer+0.4%indirect100,000 @ $14.60$1.46M

Jun 4BUYZanganeh Mahkam10%Co-Chief Executive Officer+0.4%indirect100,000 @ $14.60$1.46M

Jun 4BUYSoni Manmeet SinghCOO and CFO+0.8%direct25,000 @ $14.43$360.8K

16 more transactions on Pro →

Context

Wall St

$28.56 avg target

+63.3% vs today · 13 analysts · consensus Buy

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

1 of 4 quarters beat

Q1 '26−$0.18 act+$0.03

Q4 '25−$0.21 act−$0.20

Q3 '25−$0.23 act−$0.19

Q2 '25−$0.57 act−$0.50

Coverage

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyZacks · 06-04 Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLCInsider Monkey · 06-04 Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileSimply Wall St. · 06-04 Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical DevelopmentsInsider Monkey · 06-02

The file stays open

49 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Zanganeh Mahkam

Duggan Robert W

Xia Yu

49 filings on record.The next one will be too.

49 filings on record.
The next one will be too.